Each year 12 million people are confronted with the diagnosis of cancer, early detection is vital to reduce the mortality degree up to 30% (source WHO). Without a clear diagnosis, a second biopsy is required which increases the risks of complications and causes delays in treatments for patients.
B-PHOT participates in the European InSPECT research consortium that addresses the challenge to develop smart biophotonic devices for physicians that allow real-time diagnosis of cancer.
The integration of photonics and spectral sensing for low-cost miniature spectrometers into applications such as biopsy needles will offer patients access to faster and more accurate treatments.
The new generation of biophotonic spectrometers opens also the door to new surgical devices. According to Prof. dr. Theo Ruers, Professor of Surgical Oncology at the Netherlands Cancer Institute : "There is possibility to use those technologies in smart surgical devices so the surgeon knows exactly if he/she is cutting into tumorous or into normal tissue. Another application could be to develop implantable tissue sensors."
Discover how B-PHOT’s expertise in light-based technologies can impact healthcare watching the video that shows the opportunities of improved biopsy guidance technology in oncology.
The European InSPECT project is coordinated in The Netherlands by Philips, bringing together eight partners representing expertise in optics, photonics, device manufacturing, and medical technology: B-PHOT Vrije Universiteit Brussel (Brussels, Belgium), Xenics (Leuven, Belgium), Anteryon (Eindhoven, The Netherlands), Xio Photonics (Enschede, The Netherlands), Aifotec (Meiningen, Germany), Avantes (Apeldoorn, The Netherlands), and the Fraunhofer Institute for Reliability and Microintegration (Germany).
Visit European InSPECT for more information.